Clinical trials: E.Coli Infections
Healthy Volunteers
Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)
The research objective is to evaluate the safety and tolerability of the recombinant Group B meningococcal vaccine (E. coli) and explore its preliminary immunogenicity.
- Trial name
- NCT06314880
- Testing
- Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose), Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Positive E Coli Infections
Ampicillin-sulbactam Resistant E.Coli at UPMC
The information collected will optimize the management of patients with gram negative bacteremia. Approximately 300 patients with Gram negative bacteremia are cared for each year at UPMC-P.
- Trial name
- NCT00619580
- Where
- United States
- Sponsor
- University of Pittsburgh
Hepatitis E
Clinical Trial of Recombinant Hepatitis E Vaccine
The primary purpose of this study is to determine whether the preventive hepatitis E are effective in the prevention of hepatitis E occurring at least 30 days after the administration of the third dose of vaccine.
- Trial name
- NCT01014845
- Testing
- hepatitis E vaccine, Hepatitis B vaccine
- Where
- China
- Volunteers
- 112,604 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Beta-lactamase Extended Spectrum, E. Coli, Elderly, Mortality, Risk Factor
The Association Between Advancing Age and Mortality at 30 Days in Patients With Bacteremia E. Coli Beta-lactamase Phenotype Extended Spectrum RC15_0421
In the US and Europe, bacteremia are ranked the 7th leading cause of death from all causes. E. coli is one of the main microorganism involved, responsible for 30% to 45% of bacteremia. In Europe, bacteremia E.
- Trial name
- MoBaCo (NCT02847065)
- Where
- France
- Volunteers
- 144 people
- Sponsor
- Nantes University Hospital
Malaria
Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults
Malaria has remained a major concern for the US military. During World War II, malaria was the leading cause of disease and non-battle injury with 500-700 men infected per day, resulting in 24,000 malaria-related casualties.(10)…
- Trial name
- NCT01540474
- Testing
- Group 1: 10 ug FMP012 with 2 ug GLA-SE, Group 2: 10 ug FMP012 with 5 ug GLA-SE, 50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Infection Due to Escherichia Coli, Acute Pyelonephritis
Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli
The aim of the investigators' study was to evaluate oral and non carbapenem antimicrobial agents which can be used in outpatient for the treatment of non-bacteremic acute pyelonephritis caused by Extended Spectrum Beta Lactamase…
- Trial name
- SETAP (NCT02537847)
- Testing
- Sitafloxacin, Ertapenem
- Where
- Thailand
- Volunteers
- 96 people
- Sponsor
- Mahidol University
Diarrhea
Rifaximin for Prevention of Travellers' Diarrhea
The purpose of this study is to determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers' diarrhea compared to placebo.
- Trial name
- NCT00742469
- Testing
- Rifaximin
- Where
- Mexico
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Urinary Tract Infections
Selective Reporting of Antibiotic Susceptibility Test Results in Urinary Tract Infections in the Outpatient Setting
Antibiotic resistance is a serious and increasing worldwide threat to global public health. One of antibiotic stewardship programmes' objectives is to reduce inappropriate broad-spectrum antibiotics' prescription.
- Trial name
- NCT03612297
- Testing
- Selective reporting of Antibiotic Susceptibility Tests
- Volunteers
- 64,000 people
- Sponsor
- Central Hospital, Nancy, France
Shigella Infection, Enterotoxigenic Escherichia Coli Infection
Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122
The purpose of this study is to determine whether a live, oral, combined Shigella-ETEC vaccine candidate, known as strain CVD 1208S-122, is safe and immunogenic.
- Trial name
- NCT04634513
- Testing
- strain CVD 1208S-122
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Gastroenteritis Escherichia Coli
Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects
Enterotoxigenic Escherichia (E.) coli (ETEC) bacteria are the main cause of traveler's diarrhea and are significant pathogens affecting children and elderly individuals of developing countries.
- Trial name
- NCT00654108
- Testing
- Ciprofloxacin, Peru-15-pCTB, Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Urinary Tract Infections
Comparative Study of the Genomic Characteristics of Uropathogenic Escherichia Coli According to the Severity of Community-Acquired Urinary Tract Infections in Guadeloupe (COLIGENURI)
The aim is to identify genomic determinants (genes or gene clusters) associated with the severity of community-acquired E. coli urinary tract infections in Guadeloupe through a comparative approach integrating clinical…
- Trial name
- COLIGENURI (NCT07905638)
- Testing
- Whole-genome sequencing (WGS) of E. coli isolates (applies to all 3 groups)
- Volunteers
- 210 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Retina, Regional Blood Flow
Effect of Antioxidants on Ocular Blood Flow, Endothelial Function, and Cytokine Levels in LPS Induced Inflammatory Model in Humans.
Oxidative stress, which refers to cellular damage caused by reactive oxygen intermediates, has been implicated in many disease processes, especially age-related disorders.
- Conditions
- Retina, Regional Blood Flow, Endotoxin, Escherichia Coli
- Trial name
- NCT00431691
- Testing
- vitamin and mineral supplement, Escherichia coli Endotoxin (LPS), 100% O2
- Where
- Austria
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Urinary Tract Infection
Cranberry Proanthocyanidins for Modification of Intestinal E. Coli Flora and Prevention of Urinary Tract Infections in UTI-Susceptible Women
The purpose of the research is to determine if eating sweetened, dried cranberries or strawberry fruit pieces will increase the types of different E.
- Trial name
- NCT01219595
- Testing
- Sweetened, dried cranberries, Strawberry Fruit Pieces, Observation
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Anthrax
A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults
This study will provide preliminary safety and comparative immunogenicity data for the E.coli derived rPA vaccine administered by intramuscular (IM) injection at Day 0 and Month 1.Doses will range from 5 μg to 100 μg rPA, and at…
- Trial name
- NCT00057525
- Testing
- Anthrax, Alhdryogel or PBS
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- DynPort Vaccine Company LLC, A GDIT Company
Urinary Tract Infection
Cranberry for UTI Prevention in Residents of Long Term Care Facilities
Urinary tract infections (UTIs) affect over 7 million men and women per year and cost the health care industry over 1 billion dollars annually.
- Trial name
- PACS (NCT00596635)
- Testing
- Once Daily Cranberry Capsule, Twice Daily Cranberry Capsules
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Yale University
Hepatitis E, Hepatitis B
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)
This is a open label, randomized phase VI study, to assess the safety and immunogenicity of co-administration of Hepatitis E vaccine with Hepatitis B vaccine.
- Trial name
- NCT02584543
- Testing
- HEV vaccine, HBV vaccine
- Where
- China
- Volunteers
- 602 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Healty Volunteers, Preventable Disease, Vaccine
A Phase 2 Bridging Study to Assess the New Formulation of ETVAX
This is a phase 2,prospective double-blind, randomized, parallel-group study with the aim to demonstrate non-inferiority, in terms of immunogenicity, between the wet formulation and a newly developed partially dried formulation…
- Trial name
- NCT05178134
- Testing
- Etvax
- Where
- Sweden
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Scandinavian Biopharma AB
Gram-Positive Bacterial Infections, Escherichia Coli Infections
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in…
- Conditions
- Gram-Positive Bacterial Infections, Escherichia Coli Infections, Klebsiella Infections
- Trial name
- NCT00167999
- Testing
- piperacillin-tazobactam
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Urinary Tract Infections
Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli
Background Information: Infections caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli are becoming increasingly common owing to incorrect use of antibiotics and cross-transmission in healthcare…
- Trial name
- COLIFOX (NCT02474706)
- Testing
- Cefoxitin, imipenem
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Central Hospital, Nancy, France
Infection by Human Papilloma Virus
Lot-to-Lot Consistency Clinical Trial of Recombinant Human Papillomavirus 9-valent (Types 6/11/16/18/31/33/45/52/58) Vaccine (Escherichia Coli)
To support international market access and comply with World Health Organization Prequalification requirements, this lot-to-lot consistency trial is planned for initiation.
- Trial name
- NCT07668271
- Testing
- 9-valent HPV vaccine (Cecolin 9)
- Where
- China
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd